BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. BioMarin's products are used to treat patients suffering from rare genetic diseases such as phenylketonuria, achondroplasia, and Batten disease. The company was founded in 1997 and is headquartered in San Rafael, California.